Radtke, K. K., Hesseling, A. C., Winckler, J. L., Draper, H. R., Solans, B. P., Thee, S., . . . Garcia-Prats, A. J. (2022). Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Clinical infectious diseases, 74(8), 1372. https://doi.org/10.1093/cid/ciab641
Citácia podle Chicago (17th ed.)Radtke, Kendra K., et al. "Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children." Clinical Infectious Diseases 74, no. 8 (2022): 1372. https://doi.org/10.1093/cid/ciab641.
Citácia podľa MLA (8th ed.)Radtke, Kendra K., et al. "Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children." Clinical Infectious Diseases, vol. 74, no. 8, 2022, p. 1372, https://doi.org/10.1093/cid/ciab641.